Peter Kabos

University of Colorado Hospital — United States

Medicine · Health Sciences

37h-index4.2kcitations336works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(158), HER2/EGFR in Cancer Research(94), Estrogen and related hormone effects(55), Cancer Treatment and Pharmacology(44), Lung Cancer Research Studies(40)

Publications336 total

Supplementary Table S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Table S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Table S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Supplementary Fig. S3 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
2025Open Access
Maf1 cooperates with progesterone receptor to repress RNA polymerase III transcription of select tRNAs
Nucleic Acids Research·2025Open Access
Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Carol A. Sartorius(21), Austin E. Gillen(11), Anthony Elias(9), Jessica Finlay-Schultz(8), Diana M. Cittelly(7), Heather M. Brechbuhl(6), Sara M. Tolaney(5), Justin P.O. Lindemann(5), J. Chuck Harrell(5), Jay R. Hesselberth(5), Britta M. Jacobsen(5), Virginia F. Borges(5), Tomomi M. Yamamoto(4), Manoj M. Pillai(4), Yanyun Chen(4), Enos Kline(4), Susan M. Edgerton(4), Hope S. Rugo(4), Jennifer R. Diamond(4), Valentina Boni(4)